Researcher Spotlight: Yazeed Sawalha, MD Cleveland Clinic Patients with indolent non-Hodgkin lymphoma who relapse or have refractory lymphoma that does not respond to treatment still have poorer outcomes, with many of the current available treatments having either limited benefit or significant side effects.…
Researcher Spotlight: Manali Kamdar, MBBS University of Colorado Patients with indolent (slow-growing) lymphomas such as follicular (FL) or marginal zone (MZL) are chronic, frequently relapsing diseases which can vary widely in clinical presentation. Therapies are varied and can often include…
Researcher Spotlight: Yuxuan Liu, PhD Columbia University Medical Center Recent research has shown that genes encoding histone acetyltransferase (HAT) enzymes, EP300 and CREBBP, often become mutated in the malignant cells of follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).…
Researcher Spotlight: Elise A. Chong, MD University of Pennsylvania Perelman School of Medicine Chimeric antigen receptor (CAR) T-cell therapy has been an effective treatment for any patients with B-cell lymphomas who don’t respond to other therapies, producing remissions in 30…
Researcher Spotlight: Jianguo Tao, MD, PhD H. Lee Moffitt Cancer Center With the success of ibrutinib in mantle cell lymphoma (MCL) and other B-cell lymphomas, researchers have become focused on the problem of treatment resistance – not only do a…
Researcher Spotlight: Sandeep Dave, MD, MS Duke University Medical Center “Even as progress has been made in a number of cancers, the options for MCL patients remain disappointingly narrow,” says Dr. Dave. He and his colleagues are seeking to expand…
Researcher Spotlight: Owen A. O’Connor, MD, PhD Columbia University Medical Center A long-time member of the Lymphoma Research Foundation’s Scientific Advisory Board , and a founding Executive Committee member of LRF’s Mantle Cell Lymphoma Consortium, Dr. Owen O’Connor has been…
Researcher Spotlight: Selina Chen-Kiang, PhD Weill Cornell Lymphoma Research Foundation (LRF)- supported research may have identified both the molecular mechanism that causes some mantle cell lymphoma (MCL) patients to be resistant to ibrutinib (Imbruvica), and ways to overcome that resistance.…
Researcher Spotlight: Elias Campo, MD, PhD Hospital Clinic of the University of Barcelona in Spain Dr. Campo is Research Director and Professor of Anatomic Pathology at the Hospital Clinic of the University of Barcelona in Spain. He and his colleagues…
Researcher Spotlight: Laurence Cooper, MD, PhD MD Anderson Lymphoma Research Foundation (LRF) grantee Dr. Laurence Cooper is passionate about using the body’s immune system to fight lymphoma. He helped conduct the first in-human clinical trial of adoptive immunotherapy for patients…
